Track market-moving stories before they get noisy

CONMED Corporation (NYSE: CNMD) today announced that its [url="]AirSeal Robotic Solution[/url] is now indicated for use with Intuitive's 8 mm hex cannulas us

ELKHART, Ind.--(BUSINESS WIRE)--LCI Industries (NYSE: LCII), a leading supplier of engineered components to the recreation and transportation markets, will release its second quarter 2026 financial results before the market opens on Wednesday, August 5, 2026. Conference Call & Webcast LCI Industries will also host a conference call and webcast to discuss its second quarter 2026 results on Wednesday, August 5, 2026, at 8:30 a.m. ET. An online, real-time webcast, as well as a supplemental ear.

First BanCorp. (the “Corporation” or “First BanCorp.”) (NYSE: FBP), the bank holding company for FirstBank Puerto Rico (“FirstBank” or “the Bankâ

TORONTO, ON, July 22, 2026 (GLOBE NEWSWIRE) -- Panda Hub, the car detailing and car care platform serving customers in 100+ cities and expanding rapidly across the United States and Canada, announced a strategic investment from technology entrepreneur Matt Tagg. Tagg founded Webafrica in 1997 and built it into one of South Africa's largest internet service providers.

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG) on behalf of investors that purchased or otherwise acquired Hub Group securities between April 28, 2023 and May 11, 2026 (the “Class Period”). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an investor in Hub Group and have suffered losses, you may CLICK HERE to contact us.

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System boosted its stake in Entegris, Inc. (NASDAQ:ENTG – Free Report) by 21.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 255,615 shares of the semiconductor company’s stock after buying an additional 44,533 shares during the period. California Public Employees Retirement System owned 0.17% of Entegris worth $29,968,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ENTG. Dream Peak Capital Ltd bought a new position in Entegris in the fourth quarter worth $27,025,000. SG Americas Securities LLC boosted its holdings in shares of Entegris by 616.5% during the 4th quarter. SG Americas Securities LLC now owns 146,230 shares of the semiconductor company’s stock valued at $12,320,000 after buying an additional 125,822 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Entegris by 20.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 202,196 shares of the semiconductor company’s stock valued at $17,035,000 after buying an additional 34,894 shares in the last quarter. Perpetual Ltd grew its position in shares of Entegris by 2.7% in the 4th quarter. Perpetual Ltd now owns 418,090 shares of the semiconductor company’s stock worth $35,224,000 after buying an additional 10,889 shares during the period. Finally, Norges Bank purchased a new stake in shares of Entegris in the 4th quarter worth about $158,669,000.

Analyst Upgrades and Downgrades ENTG has been the subject of a number of recent research reports. Mizuho lifted their price target on shares of Entegris from $180.00 to $200.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. The Goldman Sachs Group restated a “sell” rating and issued a $115.00 price objective on shares of Entegris in a report on Friday, May 1st. Weiss Ratings raised shares of Entegris from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Citigroup reiterated a “buy” rating on shares of Entegris in a report on Thursday, April 30th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Entegris from $145.00 to $155.00 and gave the stock a “hold” rating in a research report on Monday, July 6th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $164.22.

Get Our Latest Analysis on Entegris

Insider Activity In related news, SVP Clinton M. Haris sold 6,848 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $149.23, for a total transaction of $1,021,927.04. Following the sale, the senior vice president directly owned 54,961 shares of the company’s stock, valued at $8,201,830.03. This trade represents a 11.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Olivier Blachier sold 2,000 shares of Entegris stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $140.04, for a total value of $280,080.00. Following the completion of the sale, the senior vice president owned 34,897 shares of the company’s stock, valued at $4,886,975.88. The trade was a 5.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 44,466 shares of company stock valued at $6,186,624. Corporate insiders own 0.53% of the company’s stock.

Entegris Stock Up 4.8% Shares of Entegris stock opened at $140.17 on Wednesday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.05 and a current ratio of 3.21. The stock has a market capitalization of $21.38 billion, a PE ratio of 81.02, a price-to-earnings-growth ratio of 1.56 and a beta of 1.31. Entegris, Inc. has a 52-week low of $67.97 and a 52-week high of $186.94. The company has a 50-day simple moving average of $146.12 and a two-hundred day simple moving average of $132.15.

Entegris (NASDAQ:ENTG – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The semiconductor company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.11. The firm had revenue of $811.90 million for the quarter, compared to analysts’ expectations of $808.72 million. Entegris had a net margin of 8.18% and a return on equity of 11.45%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 earnings per share. Entegris has set its Q2 2026 guidance at 0.760-0.840 EPS. On average, analysts anticipate that Entegris, Inc. will post 3.65 EPS for the current fiscal year.

Entegris Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 19th. Stockholders of record on Wednesday, July 29th will be paid a $0.10 dividend. The ex-dividend date is Wednesday, July 29th. This represents a $0.40 annualized dividend and a dividend yield of 0.3%. Entegris’s payout ratio is currently 23.12%.

Entegris Profile (Free Report)

Entegris, Inc is a leading provider of advanced materials and process control solutions for the semiconductor and other high-technology industries. The company develops and supplies a broad portfolio of products designed to ensure purity and reliability throughout the manufacturing process, helping customers address critical contamination and yield challenges.

Entegris’s product offerings include high-purity chemicals and specialty materials, liquid and gas filtration and purification systems, and sophisticated wafer and chip handling solutions.

See Also Five stocks we like better than Entegris Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Entegris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entegris and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Has $27.32 Million Holdings in Crown Holdings, Inc. $CCK

NEXT HEADLINE »Edwards Lifesciences Corporation $EW Shares Acquired by Andra AP fonden

Leveraging SunTrax Air's purpose-built testing environment, the initiative will help shape the infrastructure and operational framework needed to support Advanced Air Mobility and future commercial eVTOL operations.

, /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX, EVEXW; B3: EVEB31), a global leader in eVTOL aircraft and integrated services, is announcing a partnership with the Florida Department of Transportation (FDOT) for a focused Advanced Air Mobility (AAM) initiative at SunTrax Air.

The FDOT-led initiative will bring together Eve's expertise in eVTOL aircraft, operations, and services with SunTrax Air's research, testing, and validation capabilities. The effort will focus on delivering insights into the infrastructure, operational procedures, and airspace navigation procedures needed to enable the safe and efficient integration of Advanced Air Mobility into Florida's transportation network.

"Florida recognizes its strategic role in the future of Advanced Air Mobility and is proactively building the ecosystem needed to support it," said Johann Bordais, chief executive officer of Eve Air Mobility. "Chief Will Watts and the FDOT team understand that successfully introducing a new mode of transportation requires alignment across aircraft, infrastructure, operations, and communities. Building on Embraer's longstanding relationship with the state, Eve is proud to bring its expertise to help advance Florida's vision and readiness for eVTOL operations."

Owned and operated by FDOT, SunTrax Air serves as Florida's dedicated Advanced Air Mobility research and development hub, providing a collaborative environment to evaluate technologies, operational concepts, and supporting infrastructure for next-generation aviation.

"This partnership is another step of forward-progress being made in Florida toward achieving the implementation of Advanced Air Mobility," said Jared W. Perdue, P.E., FDOT Secretary. "The unique resources and infrastructure found only at SunTrax will play a key role in Eve's research and testing needed to ensure the safe integration of Advanced Air Mobility into our transportation system."

The partnership builds on the growing relationship between Eve and FDOT. Through ongoing collaboration, the organizations will work to position Florida as a national leader in AAM. Using SunTrax Air's purpose-built research and testing environment, they will evaluate operational concepts, infrastructure readiness, passenger experience, and future ecosystem requirements, creating a foundation that supports Florida's long-term transportation strategy while helping accelerate the commercialization of Advanced Air Mobility.

About Eve Air Mobility

Eve Air Mobility is dedicated to accelerating the Urban Air Mobility (UAM) ecosystem. Benefitting from a start-up mindset, backed by Embraer's 56-year history of aerospace expertise, and with a singular focus, Eve is taking a holistic approach to progressing the UAM ecosystem, with an advanced eVTOL project, comprehensive global services and support network and a unique air traffic management solution. Eve is listed on the New York Stock Exchange (EVEX; EVEXW) and the São Paulo Stock Exchange (EVEB31), where its shares of common stock, public warrants and Brazilian Depository Receipts are traded. For more information, please visit www.eveairmobility.com

Image: FDOT at the Farnborough Air Show

Forward-Looking Statement Disclosure 

Certain statements contained in this release are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by words such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "plan," "project," "could," "should," "would," "continue," "seek," "target," "guidance," "outlook," "if current trends continue," "optimistic," "forecast" and other similar words or expressions. All statements, other than statements of historical facts, are forward-looking statements, including, but not limited to, statements about the company's plans, objectives, expectations, outlooks, projections, intentions, estimates, and other statements of future events or conditions, including with respect to all companies or entities named within. These forward-looking statements are based on the company's current objectives, beliefs and expectations, and they are subject to significant risks and uncertainties that may cause actual results and financial position and timing of certain events to differ materially from the information in the forward-looking statements. These risks and uncertainties include, but are not limited to, those set forth herein as well as in Part I, Item 1A. Risk Factors and Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of the company's most recent Annual Report on Form 10-K, Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations and Part II, Item 1A. Risk Factors of the company's most recent Quarterly Report on Form 10-Q, and other risks and uncertainties listed from time to time in the company's other filings with the Securities and Exchange Commission. Additionally, there may be other factors of which the company is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ materially from those discussed. The company does not assume any obligation to publicly update or supplement any forward-looking statement to reflect actual results, changes in assumptions or changes in other factors affecting these forward-looking statements. other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statement. 

SOURCE Eve Air Mobility

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System lifted its holdings in shares of Lennar Corporation (NYSE:LEN – Free Report) by 2.3% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 313,354 shares of the construction company’s stock after buying an additional 7,103 shares during the period. California Public Employees Retirement System owned about 0.13% of Lennar worth $27,212,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the business. Lazard Asset Management LLC grew its position in Lennar by 7.1% in the second quarter. Lazard Asset Management LLC now owns 1,278 shares of the construction company’s stock valued at $141,000 after acquiring an additional 85 shares during the last quarter. Rossby Financial LCC boosted its stake in shares of Lennar by 9.1% in the 4th quarter. Rossby Financial LCC now owns 1,059 shares of the construction company’s stock valued at $109,000 after purchasing an additional 88 shares in the last quarter. New Mexico Educational Retirement Board boosted its stake in shares of Lennar by 1.0% in the 4th quarter. New Mexico Educational Retirement Board now owns 10,560 shares of the construction company’s stock valued at $1,086,000 after purchasing an additional 100 shares in the last quarter. KDT Advisors LLC grew its holdings in shares of Lennar by 2.7% during the 3rd quarter. KDT Advisors LLC now owns 4,654 shares of the construction company’s stock valued at $587,000 after purchasing an additional 123 shares during the last quarter. Finally, Orion Porfolio Solutions LLC increased its position in Lennar by 0.7% during the 4th quarter. Orion Porfolio Solutions LLC now owns 17,725 shares of the construction company’s stock worth $1,822,000 after purchasing an additional 130 shares in the last quarter. 81.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth LEN has been the topic of a number of research analyst reports. Truist Financial cut their target price on shares of Lennar from $95.00 to $90.00 and set a “hold” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Lennar in a report on Thursday, June 11th. BTIG Research set a $67.00 price target on Lennar in a research note on Monday, June 15th. Seaport Research Partners reissued a “sell” rating and set a $74.00 price objective (down from $140.00) on shares of Lennar in a report on Tuesday, April 7th. Finally, Royal Bank Of Canada lowered their target price on Lennar from $88.00 to $85.00 and set an “underperform” rating for the company in a report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, seven have given a Hold rating and ten have assigned a Sell rating to the stock. According to MarketBeat.com, Lennar has a consensus rating of “Reduce” and an average target price of $92.80.

View Our Latest Stock Report on Lennar

Lennar Trading Down 1.3% LEN opened at $81.86 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.91 and a quick ratio of 0.91. Lennar Corporation has a fifty-two week low of $81.18 and a fifty-two week high of $144.24. The company’s 50 day moving average price is $88.07 and its two-hundred day moving average price is $97.52. The firm has a market capitalization of $19.72 billion, a price-to-earnings ratio of 12.81, a PEG ratio of 2.75 and a beta of 1.38.

Lennar (NYSE:LEN – Get Free Report) last released its quarterly earnings results on Thursday, June 11th. The construction company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.07. Lennar had a net margin of 4.93% and a return on equity of 7.08%. The firm had revenue of $7.94 billion during the quarter, compared to the consensus estimate of $8.08 billion. During the same quarter last year, the firm earned $1.81 earnings per share. The company’s revenue for the quarter was down 5.2% on a year-over-year basis. As a group, research analysts predict that Lennar Corporation will post 5.52 earnings per share for the current year.

Lennar Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Friday, July 24th. Shareholders of record on Friday, July 10th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 10th. This represents a $2.00 annualized dividend and a yield of 2.4%. Lennar’s payout ratio is presently 31.30%.

Lennar Profile (Free Report)

Lennar Corporation (NYSE: LEN) is a U.S.-based homebuilder and real estate company that designs, constructs and sells residential housing. The company offers a range of product types including single-family detached homes, townhomes and condominiums, serving buyers from entry-level and first-time purchasers to move-up, active-adult and luxury segments. Lennar also develops master-planned communities and manages land acquisition and entitlement activities that support its homebuilding operations.

In addition to home construction and sales, Lennar provides a suite of ancillary services intended to streamline the purchase process and capture additional value.

Featured Articles Five stocks we like better than Lennar Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Lennar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lennar and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Purchases 12,614 Shares of International Flavors & Fragrances Inc. $IFF

NEXT HEADLINE »California Public Employees Retirement System Sells 18,426 Shares of AST SpaceMobile, Inc. $ASTS

HOUSTON--(BUSINESS WIRE)--NRG Energy, Inc. (NYSE: NRG) today announced that its Board of Directors declared a quarterly dividend on the Company's common stock of $0.475 per share, or $1.90 per share on an annualized basis. The dividend is payable on August 17, 2026, to stockholders of record as of August 3, 2026. About NRG NRG is a leading provider of electricity, natural gas, and smart home solutions to eight million customers across North America. The company operates a customer-first platfor.

July 22, 2026 08:00 ET  | Source: Inspire Medical Systems

MINNEAPOLIS, July 22, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the retirement of Casey M. Tansey from the Inspire Board after more than eighteen years of service, effective July 30.

“We are thankful for the many contributions Mr. Tansey has made to our Board of Directors over the past eighteen years,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “As one of the first venture investors to recognize the potential impact of Inspire therapy for patients with OSA, Mr. Tansey has provided valuable mentorship, leadership, and perspective throughout the Company’s founding, initial public offering and subsequent growth. We are grateful for his long-standing commitment and wish Mr. Tansey the very best in the future.”

Mr. Tansey represented U.S. Venture Partners, led Inspire’s Series A financing in November 2007 and has served on the Inspire Board of Directors since that time. The Company expects to announce the appointment of a new Director to replace Mr. Tansey in the near future.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
[email protected]
617-549-2443

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentati.

PITTSBURGH--(BUSINESS WIRE)---- $AUR #autonomoustrucking--Aurora Innovation, Inc. (NASDAQ: AUR), the leader in self-driving freight, has launched its second-generation driverless trucks. Aurora plans to deploy the new fleet across its commercial network, which currently encompasses 10 driverless routes throughout the U.S. Sun Belt, to serve additional customers.Aurora made history when it deployed Class 8 trucks powered by the Aurora Driver, its self-driving system, on public roads last year. As of the end of June, the Auro.

, /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry will release financial results for the second quarter of 2026 before the opening of the market on Thursday, August 6, 2026.

The Company will host a call the same day to discuss the results at 8:30 a.m. ET. The call will be available via webcast that can be accessed through the Investors page of Axcelis' website at www.axcelis.com, or by registering as a participant here: https://register-conf.media-server.com/register/BIf61211144e3b4baeb4c13ba3b1f529fa Webcast replays will be available for 30 days following the call.

About Axcelis:

Axcelis (Nasdaq: ACLS), headquartered in Beverly, Mass., has been providing innovative, high-productivity solutions for the semiconductor industry for over 45 years. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the most critical and enabling steps in the IC manufacturing process. Learn more about Axcelis at www.axcelis.com.

CONTACTS:

Investor Relations Contact:
David Ryzhik
Senior Vice President and Interim CFO
Telephone: (978) 787-2352
Email: [email protected]

Press/Media Relations Contact:
Maureen Hart
Senior Director, Corporate & Marketing Communications
Telephone: (978) 787-4266
Email: [email protected]

SOURCE Axcelis Technologies, Inc.

Super Micro Computer (NASDAQ: SMCI) stock surged 17% in pre-market trading on Wednesday, July 22, after the company raised its gross margin outlook.

According to an official press release, Super Micro now expects fourth-quarter fiscal 2026 gross margins of 15% to 17%, well above its previous guidance of 8.2% to 8.4%, which eased investor concerns after a challenging month that tanked share prices by 28%. 

At the same time, the firm disclosed that it booked more than $60 billion in new orders during the quarter, the highest quarterly total ever. 

While fourth-quarter revenue is still expected near the lower end of the previously issued $11-12.5 billion guidance, investors focused on the sharp improvement in margins and the strength of future demand, not near-term sales.

SMCI stock is currently trading at $25.5, while the pre-market price sits at $29.85, a level not seen since late June.

24-hour SMCI share price. Source: Google Finance Is Super Micro stock finally recovering? Super Micro is scheduled to report its full fiscal fourth-quarter results on August 11. According to analyst estimates, the company is expected to post earnings per share of $0.70, up roughly 71% from a year earlier, while revenue is forecast to more than double to approximately $11.73 billion.

A growing backlog also provides greater visibility into future sales because it represents confirmed customer demand awaiting delivery. Of course, the record order figure is particularly notable given Super Micro’s size, as $60 billion in quarterly bookings exceeds one-and-a-half times the company’s projected fiscal 2026 revenue.

However, while retail sentiment turned bullish following the announcement, some bearish concerns surrounding the company still remain. For example, the company is under scrutiny following allegations earlier this year involving the illegal export of artificial intelligence (AI) servers containing certain Nvidia (NASDAQ: NVDA) chips to Chinese customers. 

Wall Street also remains cautious despite the upbeat preliminary update. The consensus rating on Super Micro Computer stock is “Hold” as of press time, based on TipRanks data, although the average analyst price target of about $37 suggests potential upside of nearly 48% from Tuesday’s closing price.

The update also lifted sentiment across the AI server sector, with competitors such as Dell (NYSE: DELL) and HP (NYSE: HPQ) gaining between 5% and 6% in after-hours trading.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

Posted by Defense World Staff on Jul 22nd, 2026

Andra AP fonden cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 33.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,903 shares of the pharmaceutical company’s stock after selling 12,037 shares during the quarter. Andra AP fonden’s holdings in Vertex Pharmaceuticals were worth $10,674,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $1,440,149,000. Victory Capital Management Inc. boosted its position in Vertex Pharmaceuticals by 49.4% during the fourth quarter. Victory Capital Management Inc. now owns 3,356,766 shares of the pharmaceutical company’s stock valued at $1,521,851,000 after purchasing an additional 1,109,200 shares during the last quarter. Capital Research Global Investors grew its stake in Vertex Pharmaceuticals by 4.6% in the fourth quarter. Capital Research Global Investors now owns 17,316,344 shares of the pharmaceutical company’s stock valued at $7,850,544,000 after purchasing an additional 763,063 shares in the last quarter. Life Cycle Investment Partners Ltd bought a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $166,317,000. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Vertex Pharmaceuticals by 520.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 381,195 shares of the pharmaceutical company’s stock worth $149,291,000 after purchasing an additional 319,725 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance VRTX stock opened at $482.00 on Wednesday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $533.67. The stock has a market capitalization of $122.33 billion, a price-to-earnings ratio of 28.59, a PEG ratio of 2.09 and a beta of 0.29. The business’s fifty day moving average price is $464.12 and its two-hundred day moving average price is $459.39.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The company had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. During the same quarter in the previous year, the business posted $4.06 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 8.3% on a year-over-year basis. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 17.01 EPS for the current year.

Wall Street Analyst Weigh In Several analysts have issued reports on the stock. Barclays upped their price target on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Morgan Stanley boosted their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 5th. Sanford C. Bernstein dropped their target price on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a report on Tuesday, May 5th. Truist Financial raised their target price on shares of Vertex Pharmaceuticals from $542.00 to $560.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Canaccord Genuity Group reduced their price target on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a report on Tuesday, May 5th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $559.61.

Get Our Latest Analysis on Vertex Pharmaceuticals

Insider Activity In other news, Director Sangeeta N. Bhatia sold 318 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares in the company, valued at approximately $2,086,446.52. This represents a 6.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the transaction, the executive vice president directly owned 45,321 shares of the company’s stock, valued at approximately $23,793,071.79. This trade represents a 3.20% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 18,874 shares of company stock worth $8,707,966. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile (Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Featured Articles Five stocks we like better than Vertex Pharmaceuticals Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Has $12.20 Million Stock Holdings in Ferguson plc $FERG

ST. LOUIS, July 22, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.45 billion for the three months ended June 30, 2026, compared with $1.28 billion a year ago. Net income available to common shareholders was $217.2 million, or $1.34 per diluted common share, compared with $145.7 million, or $0.89 per diluted common share (1) for the second quarter of 2025.

CATSKILL, N.Y., July 22, 2026 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (NASDAQ-GCBC) today announced that its Board of Directors has approved a quarterly cash dividend of $0.11 per share on the Company's common stock. The dividend reflects an annual cash dividend rate of $0.44 per share which represents a 10.0% increase from the previous annual cash dividend of $0.40 per share.

RESTON, Va.--(BUSINESS WIRE)--John Marshall Bancorp, Inc. (Nasdaq: JMSB) (the “Company”), today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 for each share of its common stock outstanding. The dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 5, 2026. Based on the current number of shares outstanding, the aggregate payment will be approximately $1.4 million.“I am pleased to announce that our Board beli.

Posted by Defense World Staff on Jul 22nd, 2026

Andra AP fonden lifted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 144.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,928 shares of the medical equipment provider’s stock after purchasing an additional 100,406 shares during the period. Andra AP fonden’s holdings in Boston Scientific were worth $10,663,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of BSX. Renaissance Group LLC purchased a new position in shares of Boston Scientific during the 4th quarter worth $28,064,000. Rathbones Group PLC grew its holdings in shares of Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares during the period. Waycross Partners LLC acquired a new stake in Boston Scientific during the fourth quarter worth about $2,384,000. Meiji Yasuda America Inc acquired a new stake in Boston Scientific during the fourth quarter worth about $4,708,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Boston Scientific by 6.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,173,399 shares of the medical equipment provider’s stock worth $205,843,000 after purchasing an additional 139,004 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific In related news, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 9,800 shares of company stock valued at $554,012 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 1.4% BSX opened at $43.14 on Wednesday. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The business has a fifty day simple moving average of $47.77 and a 200-day simple moving average of $64.93. The firm has a market cap of $64.12 billion, a P/E ratio of 18.05, a P/E/G ratio of 0.84 and a beta of 0.58.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period last year, the business posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Corporation will post 3.35 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth Several equities analysts have weighed in on BSX shares. BTIG Research reiterated a “buy” rating and issued a $65.00 target price on shares of Boston Scientific in a report on Tuesday, June 16th. Canaccord Genuity Group reduced their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Daiwa Securities Group cut Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Evercore set a $65.00 target price on Boston Scientific in a research note on Monday, July 6th. Finally, Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $79.84.

Get Our Latest Research Report on BSX

About Boston Scientific (Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Featured Articles Five stocks we like better than Boston Scientific Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Buys 35,335 Shares of Dell Technologies Inc. $DELL

NEXT HEADLINE »Arvest Bank Trust Division Purchases Shares of 62,936 Uber Technologies, Inc. $UBER

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System decreased its stake in shares of Crown Holdings, Inc. (NYSE:CCK – Free Report) by 2.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 272,565 shares of the industrial products company’s stock after selling 7,987 shares during the period. California Public Employees Retirement System owned approximately 0.24% of Crown worth $27,325,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Royal Bank of Canada increased its holdings in Crown by 24.1% during the 1st quarter. Royal Bank of Canada now owns 48,920 shares of the industrial products company’s stock worth $4,367,000 after purchasing an additional 9,497 shares in the last quarter. Integrated Wealth Concepts LLC raised its stake in shares of Crown by 39.4% in the 1st quarter. Integrated Wealth Concepts LLC now owns 4,109 shares of the industrial products company’s stock valued at $367,000 after purchasing an additional 1,161 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Crown in the first quarter valued at about $111,000. NewEdge Advisors LLC lifted its holdings in shares of Crown by 6.3% in the first quarter. NewEdge Advisors LLC now owns 5,917 shares of the industrial products company’s stock valued at $528,000 after purchasing an additional 351 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Crown by 23.7% during the first quarter. Goldman Sachs Group Inc. now owns 666,262 shares of the industrial products company’s stock worth $59,471,000 after buying an additional 127,737 shares during the period. 90.93% of the stock is currently owned by institutional investors and hedge funds.

Key Crown News Here are the key news stories impacting Crown this week:

Positive Sentiment: Crown Holdings reported Q2 EPS of $2.49, topping estimates of $2.15, on revenue of $3.67 billion versus expectations of $3.37 billion. Crown Holdings, Inc. Reports Second Quarter 2026 Results Positive Sentiment: The company said global beverage can volumes rose 5%, signaling improving demand in a key end market for Crown’s packaging products. Crown Holdings Posts Higher Sales As Global Beverage Can Volumes Rise Positive Sentiment: Crown raised its FY2026 adjusted EPS guidance to $8.30-$8.50, above prior expectations, which supports the case for stronger earnings momentum ahead. CCK Q2 Earnings Beat on Strong Beverage Can Volumes, ’26 View Raised Positive Sentiment: Mizuho raised its price target on Crown to $135 from $130 and kept an outperform rating, reflecting a more constructive view on the stock’s upside. Benzinga report on Mizuho price target increase Neutral Sentiment: The earnings call transcript may provide additional detail on margins, demand trends, and guidance, but the headline takeaways already point to a solid quarter. Crown Holdings, Inc. (CCK) Q2 2026 Earnings Call Transcript Insider Buying and Selling at Crown In related news, CEO Timothy J. Donahue sold 15,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $105.00, for a total transaction of $1,575,000.00. Following the transaction, the chief executive officer directly owned 436,070 shares in the company, valued at approximately $45,787,350. The trade was a 3.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth A number of equities research analysts recently issued reports on CCK shares. Weiss Ratings reissued a “buy (b-)” rating on shares of Crown in a research report on Wednesday, July 8th. DA Davidson reduced their price target on Crown from $115.00 to $107.00 and set a “neutral” rating for the company in a research report on Wednesday, May 13th. Truist Financial decreased their price target on shares of Crown from $135.00 to $129.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Citigroup lifted their price objective on shares of Crown from $127.00 to $129.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. raised shares of Crown from a “neutral” rating to an “overweight” rating and set a $107.00 price objective on the stock in a research report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $124.40.

Read Our Latest Research Report on CCK

Crown Price Performance NYSE:CCK opened at $118.00 on Wednesday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 0.70 and a current ratio of 1.12. The stock’s 50-day simple moving average is $103.54 and its 200 day simple moving average is $104.90. The company has a market cap of $13.19 billion, a P/E ratio of 16.98, a P/E/G ratio of 1.91 and a beta of 0.60. Crown Holdings, Inc. has a 52-week low of $89.21 and a 52-week high of $121.76.

Crown (NYSE:CCK – Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The industrial products company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.16 by $0.33. The firm had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.37 billion. Crown had a return on equity of 27.14% and a net margin of 5.91%.During the same period in the prior year, the firm posted $2.15 earnings per share. Crown has set its Q3 2026 guidance at 2.200-2.30 EPS and its FY 2026 guidance at 8.300-8.50 EPS. As a group, sell-side analysts forecast that Crown Holdings, Inc. will post 8.06 EPS for the current fiscal year.

Crown Announces Dividend The company also recently announced a quarterly dividend, which was paid on Thursday, May 28th. Investors of record on Thursday, May 14th were paid a $0.35 dividend. The ex-dividend date of this dividend was Thursday, May 14th. This represents a $1.40 annualized dividend and a dividend yield of 1.2%. Crown’s dividend payout ratio (DPR) is currently 22.29%.

About Crown (Free Report)

Crown Holdings, Inc is a leading global supplier of rigid packaging products for consumer goods markets. The company designs, manufactures and sells metal packaging for beverage, food, household, personal care and specialty products. Its portfolio includes aluminum and steel beverage cans, steel food cans, aluminum aerosols, metal closures and ends, offering customers end-to-end solutions from design and prototyping to large-scale production.

Founded in 1919 as the Crown Cork & Seal Company, Crown has grown through strategic acquisitions and investments in advanced manufacturing technologies.

Featured Articles Five stocks we like better than Crown Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding CCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crown Holdings, Inc. (NYSE:CCK – Free Report).

Receive News & Ratings for Crown Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crown and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Boosts Holdings in Huntington Ingalls Industries, Inc. $HII

NEXT HEADLINE »California Public Employees Retirement System Buys 44,533 Shares of Entegris, Inc. $ENTG

VERNON HILLS, Ill.--(BUSINESS WIRE)--CDW Corporation (Nasdaq: CDW) announced today that it will host a webcast conference call to discuss its second quarter 2026 results on Wednesday, August 5, 2026, at 7:30 a.m. CT/8:30 a.m. ET. A live webcast (audio with slides) of the conference call will be accessible at investor.CDW.com. The press release and presentation slides will be posted on this website prior to the call. Please visit the website at least fifteen minutes prior to the call to register.

Posted by Defense World Staff on Jul 22nd, 2026

Andra AP fonden grew its stake in shares of Fair Isaac Corporation (NYSE:FICO – Free Report) by 424.4% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 8,600 shares of the technology company’s stock after acquiring an additional 6,960 shares during the quarter. Andra AP fonden’s holdings in Fair Isaac were worth $9,181,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of FICO. Bayban bought a new stake in Fair Isaac during the fourth quarter worth $25,000. Physician Wealth Advisors Inc. raised its holdings in shares of Fair Isaac by 166.7% during the 4th quarter. Physician Wealth Advisors Inc. now owns 16 shares of the technology company’s stock worth $27,000 after buying an additional 10 shares in the last quarter. Torren Management LLC bought a new stake in shares of Fair Isaac during the 4th quarter worth $30,000. Elyxium Wealth LLC bought a new position in Fair Isaac in the fourth quarter valued at about $42,000. Finally, Rakuten Securities Inc. raised its stake in Fair Isaac by 100.0% during the second quarter. Rakuten Securities Inc. now owns 24 shares of the technology company’s stock worth $44,000 after acquiring an additional 12 shares in the last quarter. Institutional investors own 85.75% of the company’s stock.

Analyst Upgrades and Downgrades FICO has been the subject of several research analyst reports. Raymond James Financial reiterated an “outperform” rating and set a $1,750.00 price target on shares of Fair Isaac in a report on Wednesday, April 29th. Barclays dropped their target price on Fair Isaac from $2,400.00 to $1,950.00 and set an “overweight” rating for the company in a research report on Friday, April 10th. Weiss Ratings upgraded Fair Isaac from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Wall Street Zen lowered shares of Fair Isaac from a “buy” rating to a “hold” rating in a report on Sunday, June 28th. Finally, Bank of America cut their target price on shares of Fair Isaac from $1,550.00 to $1,400.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Ten equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Fair Isaac has a consensus rating of “Moderate Buy” and a consensus price target of $1,627.93.

View Our Latest Analysis on Fair Isaac

Fair Isaac Trading Down 2.8% NYSE:FICO opened at $1,229.07 on Wednesday. Fair Isaac Corporation has a 12 month low of $870.01 and a 12 month high of $1,998.01. The stock has a market capitalization of $28.50 billion, a price-to-earnings ratio of 38.93, a PEG ratio of 1.12 and a beta of 1.29. The firm has a fifty day simple moving average of $1,204.37 and a two-hundred day simple moving average of $1,252.50.

Fair Isaac (NYSE:FICO – Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The technology company reported $12.50 earnings per share for the quarter, beating the consensus estimate of $11.03 by $1.47. The firm had revenue of $691.68 million for the quarter, compared to analyst estimates of $630.21 million. Fair Isaac had a net margin of 33.67% and a negative return on equity of 41.04%. The business’s quarterly revenue was up 38.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $7.81 earnings per share. Fair Isaac has set its FY 2026 guidance at 40.450-40.450 EPS. Equities analysts predict that Fair Isaac Corporation will post 38 earnings per share for the current fiscal year.

Fair Isaac Company Profile (Free Report)

Fair Isaac Corporation, commonly known as FICO, is a data analytics and software company best known for its FICO Score, a widely used credit-scoring system that helps lenders assess consumer credit risk. Founded in 1956 by Bill Fair and Earl Isaac, the company has evolved from its origins in statistical credit scoring to a broader focus on predictive analytics, decision management and artificial intelligence-driven solutions for financial services and other industries. FICO is headquartered in San Jose, California, and operates globally, serving clients across North America, Latin America, Europe, the Middle East, Africa and the Asia-Pacific region.

FICO’s product portfolio centers on analytics and decisioning technologies.

Recommended Stories Five stocks we like better than Fair Isaac Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Fair Isaac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fair Isaac and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBorgWarner Inc. $BWA Shares Acquired by California Public Employees Retirement System

NEXT HEADLINE »Revolution Medicines, Inc. $RVMD Shares Sold by California Public Employees Retirement System

Posted by Defense World Staff on Jul 22nd, 2026

Assetmark Inc. lifted its holdings in shares of Ciena Corporation (NYSE:CIEN – Free Report) by 4,003.2% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,659 shares of the communications equipment provider’s stock after purchasing an additional 16,253 shares during the quarter. Assetmark Inc.’s holdings in Ciena were worth $6,468,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Transamerica Financial Advisors LLC boosted its stake in shares of Ciena by 71.0% in the 4th quarter. Transamerica Financial Advisors LLC now owns 106 shares of the communications equipment provider’s stock valued at $25,000 after buying an additional 44 shares during the period. Truvestments Capital LLC boosted its holdings in shares of Ciena by 45.3% in the 4th quarter. Truvestments Capital LLC now owns 154 shares of the communications equipment provider’s stock valued at $36,000 after buying an additional 48 shares in the last quarter. Bogart Wealth LLC grew its holdings in shares of Ciena by 635.7% during the first quarter. Bogart Wealth LLC now owns 103 shares of the communications equipment provider’s stock worth $40,000 after purchasing an additional 89 shares during the last quarter. Acumen Wealth Advisors LLC purchased a new position in Ciena during the 4th quarter worth approximately $40,000. Finally, Wolff Wiese Magana LLC purchased a new position in shares of Ciena during the fourth quarter worth approximately $47,000. 91.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades Several equities analysts recently issued reports on the company. Bank of America boosted their price target on Ciena from $550.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Zacks Research upgraded shares of Ciena from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 2nd. TD Cowen boosted their target price on Ciena from $425.00 to $675.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Stifel Nicolaus set a $615.00 price target on shares of Ciena in a report on Friday, May 29th. Finally, Citigroup increased their price objective on Ciena from $345.00 to $658.00 and gave the company a “buy” rating in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $530.56.

View Our Latest Stock Analysis on CIEN

Insider Buying and Selling In other Ciena news, SVP Joseph Cumello sold 1,586 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $466.33, for a total transaction of $739,599.38. Following the transaction, the senior vice president owned 42,872 shares of the company’s stock, valued at $19,992,499.76. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Marc D. Graff sold 126 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $466.20, for a total value of $58,741.20. Following the transaction, the chief financial officer owned 126,955 shares in the company, valued at $59,186,421. This trade represents a 0.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,627 shares of company stock worth $10,974,985 over the last 90 days. 0.58% of the stock is currently owned by corporate insiders.

Ciena Stock Performance Shares of NYSE:CIEN opened at $407.89 on Wednesday. The company has a market cap of $57.74 billion, a P/E ratio of 135.96 and a beta of 1.27. The business’s 50-day simple moving average is $487.72 and its 200 day simple moving average is $407.13. Ciena Corporation has a one year low of $83.20 and a one year high of $637.51. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.11 and a current ratio of 2.73.

Ciena (NYSE:CIEN – Get Free Report) last posted its earnings results on Thursday, June 4th. The communications equipment provider reported $1.64 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.18. Ciena had a net margin of 7.87% and a return on equity of 18.15%. The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the company posted $0.42 earnings per share. The business’s revenue for the quarter was up 39.5% compared to the same quarter last year. On average, sell-side analysts forecast that Ciena Corporation will post 5.4 earnings per share for the current fiscal year.

About Ciena (Free Report)

Ciena Corporation (NYSE: CIEN) is a global supplier of telecommunications networking equipment, software and services. The company develops high-capacity optical transport systems and packet-optical platforms that enable service providers, cloud operators and large enterprises to build, manage and scale their networks. Ciena’s product portfolio includes coherent optical solutions, packet networking platforms and a suite of network automation software designed to optimize bandwidth, reduce latency and simplify network operations.

In addition to hardware offerings, Ciena provides professional services and support, including network design, implementation and ongoing maintenance.

Featured Articles Five stocks we like better than Ciena Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding CIEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ciena Corporation (NYSE:CIEN – Free Report).

Receive News & Ratings for Ciena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ciena and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAutomatic Data Processing, Inc. $ADP Shares Bought by Assetmark Inc.

NEXT HEADLINE »Assetmark Inc. Purchases 95,025 Shares of Grupo Cibest S.A. – Sponsored ADR $CIB

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Peabody Energy Corporation (NYSE:BTU) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Peabody, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/peabody-class-action-lawsuit.

WILMINGTON, Del., July 22, 2026 (GLOBE NEWSWIRE) -- As the world prepares for billions of new connected devices, autonomous systems, and immersive experiences that will demand more intelligent, more efficient, and more adaptive networks, InterDigital, Inc. (Nasdaq: IDCC) is revealing the expertise shaping the future of 6G in the new docu-film, “Built on Innovation: InterDigital and the Future of Connectivity.